Västra Hamnen Möter

Västra Hamnen Möter - Advenica

Västra Hamnen Möter - Precise Biometrics

Västra Hamnen Möter - Shape Robotics

Västra Hamnen Möter - Nasdaq

Västra Hamnen Möter - BPC Instruments

Västra Hamnen Möter - Arrow Lake

Västra Hamnen Möter - Safeture

Västra Hamnen Möter - Clemondo Group

Västra Hamnen Möter - Nexam Chemical Holding

Västra Hamnen Möter - Neola Medical

Västra Hamnen Möter - Xintela

Västra Hamnen Möter - Spago Nanomedical

Västra Hamnen Möter - OptiCept Technologies

CDON

Transactions

InCoax Networks

BIMobject

Qgroup

Malmö stad

Transaktioner

Sydsvenska Hem

Ongoing transactions

ProstaLund

Pågående erbjudanden

Videos

Bolagsordning

Articles of association

ProstaLund: Från utmaning till möjlighet

ProstaLund: CoreTherm Eagle flygfärdig

Bolagsstämmor

General meetings

ProstaLund: Nytt ledarskap efter turbulent höst

ProstaLund: Hack i kurvan eller bestående trend?

Completed transactions

Slutförda uppdrag

Home

Analyser

Finansiella rapporter

Financial reports

Styrelse

Research updates

Board of Directors

RugVista presenterar på Investerardagen 2 december 2021

Movinn presenterar årsrapport för 2022

Movinn presents Annual Report for 2022

SenzaGen presenterar på Investerardagen 2 december 2021

BE Group

Speqta presenterar på Investerardagen 9 juni 2022

ProstaLund presenterar Q4 2022

USWE presenterar på Investerardagen 8 juni 2021

Movinn presenterar Q1 2023

USWE presenterar Q2 2021/22

BeammWave

Chordate presenterar på Investerardagen 2 december 2022

Chordate Medical presenterar Q4 2022

ProstaLund presents Q4 2022

Chordate Medical presents Q4 2022

Ledning

USWE presenterar Q3 2021/22

USWE presenterar Q4 2021/22

aXichem presenterar Q2 2023

Bioextrax

USWE presents Q1 2022/23

Chordate Medical presents Q3 2022

Medimi presenterar Q1 2024

USWE Sports presenterar på Investerardagen 9 juni 2022

ViroGates presenterar Q1 2022

ViroGates presenterar Q2 2021

Iconovo

ViroGates presenterar Q3 2021

Movinn presenterar Q2 2023

ViroGates presenterar Q4 2021

Movinn presents Q2 2023

Chordate Medical presenterar Q2 2023

Chordate Medical presents Q2 2023

Intervju med Lipums vd Ola Sandborgh

Crunchfish presents Q2 2023

CombiGene

Chordate Medical presenterar Q1 2023

Chordate Medical presents Q1 2023

ProstaLund presenterar Q1 2024

Crunchfish presenterar Q2 2023

Bioextrax kommenterar Q2 2024

Medimi presenterar Q2 2023

Medimi presents Q2 2023

Crunchfish presents Q1 2023

Crunchfish presenterar Q1 2023

Medimi presenterar Q1 2023

Crunchfish presents Q3 2023

Medimi presents Q1 2023

Lime Technologies

Certified Adviser

Management

Cantargia

 Bioextrax presenterar Q1 2024

CombiGene presenterar och svarar på frågor

CombiGenes vd om det nya Spark-avtalet

Services

About us

Contact

Here is more information about Västra Hamnen Corporate Finance's services.

Here you will find information about Västra Hamnen Corporate Finance's ongoing and completed transactions.

Here you will find more information about Västra Hamnen Corporate Finance.

Here, Västra Hamnen Corporate Finance's information for investors is gathered.

Investor relations

Västra Hamnen Corporate Finance

An interim analysis of the OA study is expected in Q1 2025

Agreement with Region Östergötland regarding GMP production

 We keep the fair value at SEK 1.30 per share

Xintela recently extended the follow-up of the patients in the highest dose level group by six months in its OA study. The company expects an interim analysis from the 18-month follow-up in Q1 2025. Region Östergötland has assigned Xintela to develop and establish a GMP process for autologous skin cells for the treatment of burns. The deal is worth MSEK 3.6. Awaiting the license deal with EQGen Biomedical to materialise, we keep the fair value at SEK 1.30 per share.

Xintela: Activities below the surface

Xintela: Activities below the surface

Download report (pdf)

Martin Dominique

Tobias Karlsson